Jacob [Analyst] for Matt Larew's questions to Repligen Corp (RGEN) leadership • Q1 2025
Question
Jacob, on for Matt Larew, asked for an update on trends within the small biotech customer segment, specifically regarding order patterns in the quarter and whether the company remains optimistic about this group's recovery despite the challenging macro environment.
Answer
Executive Olivier Loeillot acknowledged that small biotech was the one segment that did not perform well in Q1, with sales down high-single digits, though orders were flat. He noted this segment is now less than 10% of total business and its health is linked to biotech funding, which declined significantly in Q1 2025 to $8 billion.